John Miller, MD
Family Medicine · Wooster, OHNPI 1104910330
Payments from drug & device makers
Across 116 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$377
- Amarin Pharma, Inc.$227
- Lilly USA, LLC$203
- Pfizer$105
- Bayer$94
- Novartis$78
- plus $937 from 31 others
What the payments were for
- Food & beverage$2,020100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 16 | $377 |
| Amarin Pharma, Inc. | 15 | $227 |
| Lilly USA, LLC | 13 | $203 |
| Pfizer | 7 | $105 |
| Bayer | 6 | $94 |
| Novartis | 3 | $78 |
| Boehringer Ingelheim | 4 | $73 |
| GSK | 5 | $66 |
| Astellas Pharma US Inc | 3 | $60 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Merck | 3 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Aimmune Therapeutics, Inc. | 3 | $50 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Corcept Therapeutics | 2 | $39 |
| Radius Health, Inc. | 2 | $35 |
| Amgen | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Mylan Specialty L.p. | 1 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| AstraZeneca | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Alkermes, Inc. | 1 | $22 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $21 |
| Exact Sciences | 1 | $17 |
| Novo Nordisk | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Dexcom, Inc. | 1 | $15 |
| Nalpropion Pharmaceuticals LLC | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Urovant Sciences Inc | 1 | $13 |
| Seqirus USA Inc | 1 | $13 |
| Fidia Pharma USA Inc. | 1 | $10 |
How this compares
$2,020 in reported general payments places this provider in the 75th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 18 | $44,010 |
| TrulicityDulaglutide | 75 | $36,122 |
| EliquisApixaban | 89 | $32,013 |
| MyrbetriqMirabegron | 78 | $16,530 |
| XareltoRivaroxaban | 44 | $12,537 |
| Mirabegron ErMirabegron | 26 | $10,894 |
| FarxigaDapagliflozin Propanediol | 34 | $9,831 |
| TrintellixVortioxetine Hydrobromide | 25 | $6,923 |
| TradjentaLinagliptin | 21 | $6,125 |
| Potassium Chloride | 158 | $5,068 |
| Repatha SureclickEvolocumab | 15 | $4,437 |
| Losartan Potassium | 160 | $2,907 |
| Divalproex Sodium | 51 | $2,895 |
| Fentanyl | 28 | $2,622 |
| Escitalopram Oxalate | 134 | $2,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $14 | $56,54762 claims |
| Lilly USA, LLCTrulicity | $203 | $36,12275 claims |
| PfizerEliquis | $105 | $32,01389 claims |
| Astellas Pharma US IncMyrbetriq | $60 | $16,53078 claims |
| AstraZenecaFarxiga | $26 | $9,83134 claims |
| Boehringer IngelheimTradjenta | $73 | $6,12521 claims |
| AbbVieCombigan | $377 | $2,42511 claims |
| GSKIncruse Ellipta | $66 | $1,79922 claims |
| Sanofi-aventis U.S. LLCLantus | $15 | $1,40219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Wooster
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.